Fluicell AB (SE:FLUI)
:FLUI
Want to see SE:FLUI full AI Analyst Report?
FLUI Stock Chart & Stats
kr10.00
>-kr0.01(-1.38%)
At close: 4:00 PM EST
kr10.00
>-kr0.01(-1.38%)
Day’s Range― - ―
52-Week Rangekr7.45 - kr43.10
Previous CloseN/A
Volume175.18K
Average Volume (3M)16.23K
Market Cap
kr42.17M
Enterprise Valuekr46.10M
Total Cash (Recent Filing)kr1.30M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)1.2
Beta1.12
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding1,373,703
10 Day Avg. Volume8,193
30 Day Avg. Volume16,225
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)74.56
Price to Sales (P/S)135.42
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr68.60M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure reduces refinancing risk and interest burden, preserving flexibility to invest in R&D and product commercialization. Over 2-6 months this supports survivability and strategic optionality while management pursues commercial traction and partnerships.
Revenue Rebound And Positive Gross ProfitA near-doubling of TTM revenue with positive gross profit signals improving product-market fit and better unit economics. Sustained top-line momentum and gross margin recovery underpin longer-term path to operating leverage as scale increases.
Niche Microfluidics Platform In Growth AreaSpecialization in microfluidics for single-cell/tissue research targets structurally growing markets (single-cell biology, regenerative medicine). A focused product set and technical differentiation can sustain competitive advantage as adoption in academia and industry expands.
Bears Say
Persistent Negative Cash FlowOngoing negative operating and free cash flow indicate the company cannot self-finance growth yet and will need external funding. This structural cash burn elevates dilution or financing risk over the next several quarters and limits reinvestment capacity.
Operating And Net Losses PersistContinued operating and net losses mean the firm has not reached profitable scale; margins remain deeply negative. Persistent losses constrain ability to build reserves, make sustained R&D or commercial investments without recurring capital raises.
Reliance On External FundingNegative ROE, fluctuating equity and explicit dependence on funding show capital structure instability. Reliance on external capital raises increases execution risk, potential dilution, and vulnerability to funding market conditions over the medium term.
FLUI FAQ
What was Fluicell AB’s price range in the past 12 months?
Fluicell AB lowest stock price was kr7.45 and its highest was kr43.10 in the past 12 months.
What is Fluicell AB’s market cap?
Fluicell AB’s market cap is kr42.17M.
When is Fluicell AB’s upcoming earnings report date?
Fluicell AB’s upcoming earnings report date is Aug 14, 2026 which is in 82 days.
How were Fluicell AB’s earnings last quarter?
Fluicell AB released its earnings results on May 08, 2026. The company reported kr2.409 earnings per share for the quarter, beating the consensus estimate of N/A by kr2.409.
Is Fluicell AB overvalued?
According to Wall Street analysts Fluicell AB’s price is currently Overvalued.
Does Fluicell AB pay dividends?
Fluicell AB does not currently pay dividends.
What is Fluicell AB’s EPS estimate?
Fluicell AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fluicell AB have?
Fluicell AB has 1,373,703 shares outstanding.
What happened to Fluicell AB’s price movement after its last earnings report?
Fluicell AB reported an EPS of kr2.409 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 48.444%.
Which hedge fund is a major shareholder of Fluicell AB?
Currently, no hedge funds are holding shares in SE:FLUI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fluicell AB
Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.